Webinars
Strategic Considerations for Scaling Up the Manufacturing of Cell Therapies
Join us as our panel of experts discuss key manufacturing challenges for early and late-stage gene-enabled cell therapy programs, as well as how to overcome them through effective partnerships.
View Now
Webinars
Overcoming Manufacturing Challenges for Gene-Enabled Cell Therapies
Summary: Join us as our panel of experts discuss key manufacturing challenges for early and late-stage gene-enabled cell therapy programs, as well as how to overcome them through effective partnerships.
View Now
Executive Summary
Scale-up Strategies for Late-stage Cell Therapies
Summary: In this executive summary, discover how Catalent’s Manufacturing by Design (MbD) strategy can help achieve efficiencies, drive cost savings, and develop and implement a robust, reproducible manufacturing plan for late-stage and commercial launch.
View Now
Video
iPSCs, a Universal Starting Material for Cell Therapies
Summary: iPSCs are a critical starting material and enable the availability of next-generation cell therapies for broad patient populations. Learn more about Catalent’s GMP iPSC capabilities including reprogramming, differentiation, and cell banking, and how they can create a path to make cell therapies more accessible.
View Now
Webinars
Webinar: Scale-up Strategies for Late-stage Cell Therapies
Summary: In this webinar, we explore the considerations that need to be taken during development to ensure manufacturing processes and our facilities can support...
View Now
Offering Fact Sheet
Industrializing iPSC-Based Cell Therapies
Summary: Our iPSC banks utilize specialized reprogramming technology to transform commercial-use donor consented, clinically approved, cord blood collections into HLA-homozygous lines that are immune compatible with a wide population.
View Now
Webinars
Accelerating Manufacturing for Next Generation hiPSC-Based Clinical Therapies
Summary: During this session, we review progress in several areas of advanced development and their impact on readiness for large scale manufacturing.
View Now
Video
An Interview: Potential of iPSCs
Summary: In this informative interview with Phacilitate, Boris Greber and Thomas Marx answer questions about the position of induced pluripotent stem cells in today’s advanced therapies market and the transformative power latent in their clinical application.
View Now
eBook
Cellular Starting Materials In Focus
Summary: In this ebook, we bring you expert insights into the advantages that various cellular starting materials have, with a particular focus on human induced pluripotent stem cells (iPSCs).
View Now
Article
An Interview: Spotlight on iPSCs
Summary: Catalent and RegMedNet showcase how induced pluripotent stem cells can catalyze the advancement of novel cell therapies. This feature explores biological, clinical and commercial characteristics of iPSCs as ideal starting materials.
View Now